Literature DB >> 16611167

Roles of type 10 17beta-hydroxysteroid dehydrogenase in intracrinology and metabolism of isoleucine and fatty acids.

X-Y He1, S-Y Yang.   

Abstract

Human type 10 17beta-hydroxysteroid dehydrogenase (HSD) is a homotetrameric protein located in mitochondria. This enzyme was alternatively named short chain L-3-hydroxyacyl-CoA dehydrogenase (SCHSD). This NAD(H)-dependent dehydrogenase is essential for the metabolism of branched-chain fatty acids and isoleucine, and is expressed in a variety of tissues, e.g., prostate, brain, liver, and heart. This enzyme inactivates 17beta-estradiol and exhibits a strong oxidative 3alpha-HSD activity to convert 5alpha-androstanediol and allopregnanolone into 5alpha-dihydrotestosterone (5alpha-DHT) and 5alpha-dihydroprogesterone, respectively, in living cells. Certain malignant prostatic epithelial cells and activated astrocytes in Alzheimer's disease patient's brain contain extraordinarily high levels of this enzyme. This mitochondrial dehydrogenase enables prostate cancer cells to generate 5alpha-DHT in the absence of testosterone. Its inactivation of allopregnanolone is important to the modulation of GABA(A) receptor. Among steroidogenic enzymes 17beta-HSD10 plays a significant part in the intracrinology. Although this protein has an affinity for amyloid-beta peptide, its role in the pathogenesis of Alzheimer's disease is far from clear. Additional knowledge of this versatile enzyme would provide the foundation for designing new drugs aimed at treating some neurological diseases and certain types of cancers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16611167     DOI: 10.2174/187153006776056639

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  9 in total

Review 1.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery.

Authors:  Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

2.  Mental retardation linked to mutations in the HSD17B10 gene interfering with neurosteroid and isoleucine metabolism.

Authors:  Song-Yu Yang; Xue-Ying He; Simon E Olpin; Vernon R Sutton; Joe McMenamin; Manfred Philipp; Robert B Denman; Mazhar Malik
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

3.  The phosphotyrosine interactome of the insulin receptor family and its substrates IRS-1 and IRS-2.

Authors:  Stefan Hanke; Matthias Mann
Journal:  Mol Cell Proteomics       Date:  2008-11-11       Impact factor: 5.911

4.  Transcription start sites and epigenetic analysis of the HSD17B10 proximal promoter.

Authors:  Song-Yu Yang; Carl Dobkin; Xue-Ying He; W Ted Brown
Journal:  BMC Biochem       Date:  2013-07-08       Impact factor: 4.059

5.  Systematic analysis of potential targets of the curcumin analog pentagamavunon-1 (PGV-1) in overcoming resistance of glioblastoma cells to bevacizumab.

Authors:  Adam Hermawan; Herwandhani Putri
Journal:  Saudi Pharm J       Date:  2021-10-05       Impact factor: 4.330

6.  3-Hydroxyacyl-CoA and Alcohol Dehydrogenase Activities of Mitochondrial Type 10 17β-Hydroxysteroid Dehydrogenase in Neurodegeneration Study.

Authors:  Xue-Ying He; Carl Dobkin; W Ted Brown; Song-Yu Yang
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

7.  The Mitochondrial Enzyme 17βHSD10 Modulates Ischemic and Amyloid-β-Induced Stress in Primary Mouse Astrocytes.

Authors:  Vanya Metodieva; Terry Smith; Frank Gunn-Moore
Journal:  eNeuro       Date:  2022-10-06

8.  Multiple short-chain dehydrogenases/reductases are regulated in pathological cardiac hypertrophy.

Authors:  Elise Roussel; Marie-Claude Drolet; Anne-Marie Lavigne; Marie Arsenault; Jacques Couet
Journal:  FEBS Open Bio       Date:  2018-09-17       Impact factor: 2.693

Review 9.  Repurposing Antipsychotics for Cancer Treatment.

Authors:  Nikolaos Vlachos; Marios Lampros; Spyridon Voulgaris; George A Alexiou
Journal:  Biomedicines       Date:  2021-11-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.